Galsulfase is administered as an intravenous (IV) infusion and must be given by a healthcare professional in a clinical setting (hospital or infusion center) where emergency medical equipment and trained personnel are readily available to manage potential serious infusion-related reactions.

• Administration Method: Intravenous infusion into a vein.
• Dosage Calculation: The dose is calculated based on the patient’s body weight.
• Preparation: The galsulfase concentrate must be diluted with 0.9% Sodium Chloride Injection, USP, using aseptic techniques, to a final volume of typically 250 mL (or 100 mL for patients weighing 20 kg or less or those susceptible to fluid overload). The solution should be gently rotated, not shaken. It does not contain preservatives, so it should be used immediately after dilution or stored refrigerated and used within 48 hours.
• Infusion Rate: The infusion is typically administered over a period of no less than 4 hours. The initial infusion rate is usually slow (e.g., 6 mL per hour for the first hour) and can be gradually increased if well-tolerated. The infusion rate may be adjusted or temporarily stopped if infusion-related reactions occur.
• Frequency: The recommended dosage regimen for galsulfase is once weekly.
• Pre-treatment: To reduce the risk of infusion-related reactions, patients may be pre-treated with antihistamines (e.g., diphenhydramine) with or without antipyretics (e.g., acetaminophen) approximately 30 to 60 minutes prior to the start of the infusion.
• Monitoring: Patients are closely monitored during and for a period after the infusion for any signs of adverse reactions, particularly hypersensitivity reactions.

This is a long-term therapy that requires ongoing, regular infusions for continued benefit.

In individuals with MPS VI, a genetic defect leads to a deficiency or absence of the enzyme N-acetylgalactosamine 4-sulfatase (ASB). This enzyme is a lysosomal hydrolase, meaning it works inside cellular compartments called lysosomes to break down specific substances. In MPS VI, ASB is needed to catalyze the breakdown of dermatan sulfate, a type of glycosaminoglycan (GAG).

When ASB is deficient, dermatan sulfate cannot be properly degraded and thus accumulates within the lysosomes of various cells throughout the body. This accumulation disrupts normal cellular function, leading to the progressive symptoms of MPS VI.

Galsulfase works by:

• Exogenous Enzyme Supply: It provides an external source of the N-acetylgalactosamine 4-sulfatase enzyme.
• Cellular Uptake and Lysosomal Targeting: When infused intravenously, galsulfase is taken up by cells into their lysosomes. This uptake is primarily mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains on galsulfase to specific mannose-6-phosphate receptors on cell surfaces.
• Substrate Catabolism: Once inside the lysosomes, galsulfase becomes active and catalyzes the cleavage of sulfate ester from dermatan sulfate, effectively breaking it down.
• Reduction of Accumulation: By increasing the catabolism of dermatan sulfate, galsulfase reduces its systemic accumulation, thereby reducing the cellular and organ dysfunction that drives the primary symptoms of MPS VI.

This enzyme replacement helps to slow the progression of the disease and can improve certain physical symptoms.

Like all medications, Galsulfase can cause side effects, with infusion-related reactions being the most common. Patients are monitored closely during infusions.

Common side effects (often infusion-related reactions, occurring in 10% or more of patients):

• Infusion-related reactions: These are the most frequent, including fever, chills, rash, hives (urticaria), shortness of breath (dyspnea), nausea, vomiting, itching (pruritus), redness (erythema), headache, abdominal pain, chest pain, dizziness, flushing, and hypertension (high blood pressure) or hypotension (low blood pressure). These can occur during or up to 24 hours after infusion.
• Headache
• Fever (pyrexia)
• Chills
• Abdominal pain
• Nausea / Vomiting
• Rash / Hives / Itching
• Cough / Runny nose / Stuffy nose
• Joint pain (arthralgia)
• Back pain
• Sore throat
• Ear pain
• Diarrhea

More serious, but less common, side effects that require immediate medical attention:

• Serious Allergic Reactions (Anaphylaxis): Life-threatening allergic reactions, including anaphylaxis, are possible. Symptoms include severe difficulty breathing, swelling of the face, tongue, or throat, severe dizziness, chest pain, and collapse. These can occur during or up to 24 hours after the infusion.
• Spinal Cord Compression (SCC): While SCC is a common complication of MPS VI itself, there have been reports of worsening SCC in patients receiving galsulfase. Symptoms include back pain, weakness or numbness in limbs, and loss of bladder or bowel control. Any new or worsening neurological symptoms should be reported immediately.
• Fluid Volume Overload and Cardiac/Respiratory Issues: Caution is advised in patients susceptible to fluid overload (e.g., those with heart or lung disease, or weighing less than 20 kg), as the volume of infusion could exacerbate conditions like congestive heart failure.
• Kidney problems: Rarely, some patients may experience bloody or cloudy urine, high blood pressure, or swelling of the face, feet, or lower legs, which could indicate kidney issues.
• Antibody Development: Patients can develop antibodies to galsulfase, which may reduce its effectiveness or increase the likelihood of infusion-related reactions.

Report any new, unusual, or severe symptoms to your doctor immediately.

Due to the nature of the drug and the disease it treats, several critical warnings and precautions are associated with galsulfase:

• Hypersensitivity Reactions (including Anaphylaxis): This is the most significant warning. Severe and life-threatening hypersensitivity reactions, including anaphylaxis, are possible. These reactions can occur at any time during the treatment course (even after many infusions) and may be delayed (up to 24 hours post-infusion) and prolonged. Infusion should be stopped immediately if a severe reaction occurs, and appropriate medical treatment (e.g., epinephrine) should be initiated. Administration must be in a clinical setting with full resuscitation capabilities.
• Infusion-Related Reactions (IRRs): IRRs are common. Pre-treatment with antihistamines and antipyretics is recommended to mitigate these reactions. Management includes slowing or temporarily stopping the infusion, or administering additional medications.
• Spinal Cord Compression (SCC): Patients with MPS VI are at risk of SCC due to bone and cartilage abnormalities. While galsulfase can address systemic GAG accumulation, its direct impact on existing structural damage leading to SCC is unclear, and some reports suggest possible worsening. Patients should be monitored for signs and symptoms of SCC. Surgical intervention may still be necessary for SCC.
• Fluid Volume Overload: Caution is required when administering galsulfase to patients susceptible to fluid overload (e.g., those under 20 kg, or with underlying respiratory, cardiac, or renal compromise), as the infusion volume could worsen these conditions.
• Immunogenicity: Patients may develop antibodies to galsulfase. The clinical impact of antibody development is variable but can include reduced therapeutic response or increased frequency/severity of infusion reactions.
• Renal and Hepatic Impairment: The safety and efficacy of galsulfase in patients with severe renal or hepatic impairment have not been formally evaluated, and no specific dose recommendations can be made for these populations.
• Pregnancy and Lactation: Limited data exist regarding galsulfase use in pregnant or breastfeeding women. It should be used during pregnancy only if clearly needed. Discuss the risks and benefits with your doctor.

There are no specific known drug-drug interactions with galsulfase that have been extensively studied or are commonly reported. As a recombinant protein, galsulfase is primarily broken down through proteolytic degradation (like other proteins) rather than by the cytochrome P450 enzyme system, which is responsible for metabolizing many common medications. Therefore, it is generally considered to have a low potential for direct metabolic drug interactions.

However, it is always crucial to inform your doctor, pharmacist, and healthcare team about all medications you are currently taking. This includes:

• Prescription drugs
• Over-the-counter medicines
• Vitamins
• Herbal products and supplements

This information is important for the healthcare team to:

• Assess overall health: Patients with MPS VI often require various supportive treatments (e.g., analgesics for pain, antibiotics for respiratory infections, medications for cardiac complications).
• Manage potential infusion-related reactions: Some medications might be used as pre-treatment (e.g., antihistamines, antipyretics) before galsulfase infusion to prevent or reduce infusion-related reactions.
• Address co-morbidities: MPS VI can affect multiple organ systems (heart, lungs), and medications for these conditions must be managed carefully.
• Consider potential for immune reactions: While not a direct interaction, the body can develop antibodies to galsulfase (immunogenicity), which can impact its effectiveness or increase the risk of infusion reactions. Other immune-modulating drugs could theoretically influence this.

The dosage of galsulfase is determined by the patient’s body weight and is administered as a long, weekly intravenous infusion.

• Recommended Dose: 1 mg per kilogram (kg) of body weight.
• Frequency: Administered once every week.
• Administration: As an intravenous infusion.
• Infusion Duration: The total volume of the diluted solution should be delivered over a period of no less than 4 hours. The initial infusion rate is slow and gradually increased if tolerated. In cases of infusion reactions, the infusion rate may be reduced, or the infusion may be temporarily stopped and restarted at a slower rate, potentially extending the total infusion time up to 20 hours.
• Dilution: Each vial (5 mg/5 mL) must be diluted with 0.9% Sodium Chloride Injection, USP, to a final volume of 250 mL (or 100 mL for patients under 20 kg or those prone to fluid overload).
• Pre-treatment: Pre-treatment with antihistamines and/or antipyretics is recommended 30-60 minutes prior to infusion to reduce the risk of infusion-related reactions.
• Monitoring: Patients are closely monitored during the entire infusion and for a period afterward for any adverse reactions.

The treatment is long-term, and consistent weekly infusions are critical for managing MPS VI.

Galsulfase (Naglazyme) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system globally. Its strict prescription requirements are due to several crucial factors:

• Treatment of a Rare, Complex Genetic Disorder: It addresses Mucopolysaccharidosis VI, a severe, life-threatening genetic condition that requires highly specialized diagnostic and management expertise.
• Specialist Oversight: Treatment must be initiated and supervised by a physician experienced in the management of patients with MPS VI or other inherited metabolic diseases.
• Intravenous Administration: It is an IV infusion, requiring administration by trained healthcare professionals in a hospital or specialized infusion clinic setting.
• Risk of Severe Infusion-Related Reactions: The potential for life-threatening hypersensitivity and infusion-related reactions necessitates a clinical environment with immediate access to emergency medical equipment and trained personnel.
• Ongoing Monitoring: Patients require continuous monitoring for response to therapy, potential side effects, and progression of the disease.
• High Cost and Orphan Drug Status: As a specialized biologic for a rare disease, it typically has a very high cost, and its use is often subject to specific criteria and funding approvals by healthcare systems.

Therefore, a licensed medical doctor, typically a geneticist, metabolic specialist, or a physician specializing in lysosomal storage disorders, must prescribe galsulfase.

What is Galsulfase used for? Treatment of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome)

2. What is the active ingredient? Recombinant human N‑acetylgalactosamine‑4‑sulfatase

3. What drug class does it belong to? Enzyme replacement therapy (ERT)

4. Is Galsulfase a controlled substance? No

5. Is Galsulfase available in generic form? No

6. How is Galsulfase administered? Intravenous infusion

7. What strengths are available? 1 mg/mL solution in single‑use vials

8. What is the usual adult dosage? 1 mg/kg body weight once weekly IV infusion

9. Can it be used in children? Yes—approved for pediatric patients with MPS VI

10. What are common side effects? Fever, rash, headache, nausea, vomiting, abdominal pain, infusion site reactions

11. Can it cause serious reactions? Yes—anaphylaxis, severe allergic reactions, respiratory distress

12. Is Galsulfase safe during pregnancy? Limited data; use only if benefits outweigh risks

13. Is a prescription required? Yes

14. Is Galsulfase available in Pakistan? Not widely; may be accessed via international specialty import

15. How should it be stored? Refrigerated at 2–8°C; protect from light; do not freeze

16. What precautions should be taken during use? Premedicate with antihistamines/antipyretics to reduce infusion reactions; monitor closely during infusion

17. What are contraindications? Hypersensitivity to galsulfase or excipients

18. What monitoring is needed during use? Infusion reactions, respiratory status, antibody development, disease progression

19. Can Galsulfase be combined with other therapies? Supportive care (analgesics, physiotherapy, surgery) may be combined; no other ERT for MPS VI

20. What are similar drugs? Other ERTs for lysosomal storage disorders: Laronidase (Aldurazyme, MPS I), Idursulfase (Elaprase, MPS II), Elosulfase alfa (Vimizim, MPS IVA)